Notice of Annual General Meeting

The Annual General Meeting of Targovax ASA (the "Company") will be held at the Company’s offices at Lysaker, on 30 April 2019 at 13:00 CET.

Please find the notice including agenda for the General Meeting and appendices attached to this disclosure. The notice and appendices will also be made available on Targovax’ website https://www.targovax.com/en/section/governance/general-meetings/.

Notice of attendance must be received no later than 29 April 2019 at 16:00 CET.

Reference is also made to the Company's stock exchange announcement on 27 March 2019 regarding the terms and conditions for the proposed subsequent offering in the Company. The Company's board of directors has proposed to re-schedule the subscription period in the subsequent offering, since the Company expects to read out 3-year survival data for TG01 during this new subscription period. The re-scheduled subscription period will commence at 09:00 hours (CEST) on 10 May 2019 and expire at 16:30 hours (CEST) on 24 May 2019.

1904 TRVX - Notice AGM 30 April 2019

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient's immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It has been shown to activate the immune system to generate tumor-specific immune responses. In phase I trials, ONCOS-102 induced both local and systemic innate and adaptive immune activation, which has been associated with clinical benefit. ONCOS-102’s targeted path-to-market indication is mesothelioma, where the virus is currently being tested in a randomized phase II trial. Another trial, in checkpoint inhibitor refractory advanced melanoma, is expected to produce important proof-of-concept immune activation data in heavily pre-treated patients.

Targovax is also developing a neo-antigen cancer vaccine targeting tumors with oncogenic RAS–mutations, which are known to drive cancer. The TG vaccine program has shown strong RAS-specific immune activation and a signal of clinical efficacy in a 32-patient trial with TG01 in resected pancreatic cancer. A next generation product candidate, TG02 is currently tested in a phase I trial in colorectal cancer, both as monotherapy and in combination with Keytruda (an anti-PD1 check point inhibitor).